What question did this study set out to answer?

Evaluate the efficacy of long-acting GM-CSF as a countermeasure for hematopoietic acute radiation syndrome (H-ARS).

LA-GM-CSF, a Long-Acting Cytokine Mitigates and Prevents H-ARS Mediated Lethality in Mice Exposed to Total Body Gamma Radiation

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates LA-GM-CSF effect on survival and recovery in mice exposed to radiation, indicating promising radiomitigator potential.

Evaluate the efficacy of long-acting GM-CSF as a countermeasure for hematopoietic acute radiation syndrome (H-ARS).
Assessed single and multi-dose regimens of LA-GM-CSF in male and female C57BL/6 mice post-total body irradiation (TBI).
Monitored safety, survival, hematologic recovery, and pharmacokinetics over 30 days after exposure.
Utilized standard hematology, histopathology, ELISA, and multiplex assays for analysis.
LA-GM-CSF showed significant survival benefits compared with vehicle control, especially at 3 mg/kg dose with 30-day survival improvement.
Post-TBI single dose administration 24 hours after exposure led to enhanced survival rates in both sexes, with males showing stronger recovery.
Accelerated recovery of neutrophils, red blood cells, and hematocrit was observed alongside favorable modulation of endothelial injury markers.

Holmes-Hampton et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates LA-GM-CSF effect on survival and recovery in mice exposed to radiation, indicating promising radiomitigator potential.

Evaluate the efficacy of long-acting GM-CSF as a countermeasure for hematopoietic acute radiation syndrome (H-ARS).
Assessed single and multi-dose regimens of LA-GM-CSF in male and female C57BL/6 mice post-total body irradiation (TBI).
Monitored safety, survival, hematologic recovery, and pharmacokinetics over 30 days after exposure.
Utilized standard hematology, histopathology, ELISA, and multiplex assays for analysis.
LA-GM-CSF showed significant survival benefits compared with vehicle control, especially at 3 mg/kg dose with 30-day survival improvement.
Post-TBI single dose administration 24 hours after exposure led to enhanced survival rates in both sexes, with males showing stronger recovery.
Accelerated recovery of neutrophils, red blood cells, and hematocrit was observed alongside favorable modulation of endothelial injury markers.

Holmes-Hampton et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark